Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Alcon to Invest US$3 Bil. in R&D over the Next 5 Years
October 22, 2007
- BUSINESS NEWS IN BRIEF
October 22, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 22, 2007
- Diovan Keeps Top Position for 5 Consecutive Months
October 22, 2007
- MEDICAL DEVICE NEWS IN BRIEF
October 22, 2007
- Major Domestic Companies Must Overcome 2010 Crisis
October 22, 2007
- Medtronic's Implantable Holter ECG Recommended for Fast-Track Review
October 22, 2007
- CFS and Ain Pharmaciez to Merge in April 2008
October 22, 2007
- REGULATORY NEW IN BRIEF
October 22, 2007
- Nipro Licenses Double-Bag Kit Product to CWP in South Korea
October 22, 2007
- Main Price Survey to Target Transactions Made in September
October 22, 2007
- MEDRx Developing Products Using its Innovative DDS Technology
October 22, 2007
- Business Owners"Burden Is Lighter in Japan than in Other Countries: Mr Hara
October 22, 2007
- Sanofi-aventis Aims at 31 Submissions by the End of 2010
October 22, 2007
- DIA Workshop Focuses on Collaborative Clinical Trials in Asia
October 22, 2007
- R&D NEWS IN BRIEF
October 22, 2007
- SymBio Begins PI Study of SyB-0702 in US
October 22, 2007
- MediciNova Reports Positive PIIa Results for MN-221 for Status Asthmaticus
October 22, 2007
- PMDA Introduces New Training Program to Upgrade Its Reviewers
October 22, 2007
- BUSINESS NEWS IN BRIEF
October 15, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…